Muhammad Salim, MD
Cardiovascular Disease · Norman, OKNPI 1407897259
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.6% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $2,273 and has fallen 80.6% since, to $440 in 2025.
Across 203 payments — averaging $40.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Novartis$393
- Pfizer$301
- Johnson & Johnson$257
- E.r. Squibb & Sons, L.L.C.$186
- Abiomed$160
- plus $1K from 22 others
What the payments were for
- Grants$1,12314%
- Travel & lodging$2,91635%
- Food & beverage$4,27351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 71 | $5,788 |
| Novartis | 23 | $393 |
| Pfizer | 19 | $301 |
| Johnson & Johnson(2 entities) | 14 | $257 |
| E.r. Squibb & Sons, L.L.C. | 12 | $186 |
| Abiomed | 4 | $160 |
| Philips North America LLC | 7 | $142 |
| Boston Scientific | 5 | $138 |
| Abbott | 8 | $127 |
| Boehringer Ingelheim | 6 | $109 |
| Novo Nordisk | 4 | $84 |
| Amgen | 4 | $71 |
| Kestra Medical Technology Services, Inc. | 2 | $64 |
| Inari Medical, Inc. | 3 | $57 |
| Edwards Lifesciences | 1 | $52 |
| W. L. Gore & Associates, Inc. | 1 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Cordis US CORP. | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $30 |
| Terumo Medical Corporation | 2 | $26 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Stryker | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,246
- 3F$1,123
- COREVALVE EVOLUT R$1,118
- Micra$269
- Impella$108
- AURORA EV-ICD MRI SURESCAN$107
How this compares
$8,313 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 582 | $660,491 |
| XareltoRivaroxaban | 102 | $132,997 |
| EntrestoSacubitril/Valsartan | 122 | $124,106 |
| FarxigaDapagliflozin Propanediol | 73 | $62,229 |
| JardianceEmpagliflozin | 41 | $40,948 |
| BrilintaTicagrelor | 67 | $37,319 |
| Repatha SyringeEvolocumab | 43 | $24,829 |
| Repatha SureclickEvolocumab | 27 | $17,395 |
| MultaqDronedarone Hcl | 15 | $16,478 |
| Metoprolol Succinate | 804 | $12,649 |
| Rosuvastatin Calcium | 639 | $12,585 |
| Valsartan | 291 | $7,193 |
| Dofetilide | 36 | $5,393 |
| ClopidogrelClopidogrel Bisulfate | 397 | $5,371 |
| Atorvastatin Calcium | 349 | $4,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $301 | $660,491582 claims |
| Johnson & JohnsonXarelto | $257 | $132,997102 claims |
| NovartisEntresto | $393 | $124,106122 claims |
| Boehringer IngelheimJardiance | $109 | $40,94841 claims |
| Sanofi-aventis U.S. LLCMultaq | $46 | $16,47815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Norman
- Archana GautamNorman$21K
- Michael SellersNorman$6K
- Jeffrey CrookNorman$6K
- Norman AyersNorman$6K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.